Tandem Diabetes Care Inc (NASDAQ: TNDM)

Tandem Diabetes Care Inc specializes in the design, development, and commercialization of advanced insulin delivery systems and diabetes technology. The company is a global leader in insulin delivery and diabetes technology, focusing on solutions that reduce the burden of diabetes management. Tandem serves nearly 500,000 people living with diabetes in more than 25 countries worldwide. The company's strategy revolves around offering flexibility and choice in intelligent insulin delivery systems through a portfolio of market-leading pumps, applications, and insights. Tandem's pump platforms include the t:slim X2 and Tandem Mobi, both featuring Control-IQ+ advanced hybrid closed-loop technology.

Tandem Diabetes Care generates revenue through the sale of its insulin pumps, single-use supplies, and related technology solutions. The company's primary products include the t:slim X2 and Tandem Mobi pumps, which are designed for years of daily use. These pumps feature Control-IQ+ technology, which is indicated for people as young as ages 2+ (type 1) and ages 18+ (type 2) in the United States. Tandem also sells single-use supplies such as cartridges for storing insulin and infusion sets that connect the pump to the user's body. The company's customer base includes people living with type 1 and type 2 diabetes who require intensive insulin therapy. Tandem's technology solutions are available in more than 25 countries, with a significant presence in the United States and Canada.

• Insulin Pumps: Tandem's flagship products are the t:slim X2 and Tandem Mobi pumps. The t:slim X2 is a durable insulin pump designed for long-term use, featuring Control-IQ+ technology, remote software updates, and an integrated color touchscreen. The Tandem Mobi is a smaller, more portable pump that also features Control-IQ+ technology and smartphone control. Both pumps are designed to integrate with continuous glucose monitoring (CGM) sensors such as the Dexcom G6 and G7, and the Abbott FreeStyle Libre 2 Plus and 3 Plus. These pumps cater to the market of people with insulin-dependent diabetes, providing them with advanced hybrid closed-loop technology to manage their condition more effectively.

• Single-Use Supplies: Tandem sells single-use supplies that are used together with its pumps. These supplies include cartridges for storing insulin and infusion sets that contain a cannula and connect the pump to the user's body. The infusion sets are manufactured by Unomedical A/S, a subsidiary of the ConvaTec Group, under Tandem's brands. These supplies cater to the same market as the insulin pumps, providing essential components for the effective use of Tandem's insulin delivery systems.

• Software and Applications: Tandem offers several software and application solutions to support its insulin pumps. The Tandem Device Updater allows pump users to update their pump software quickly and easily from a personal computer. Tandem Source is a web-based data management platform that provides users, their caregivers, and healthcare providers with a fast, easy, and visual way to display diabetes therapy management data. Sugarmate is a mobile app designed to help people visualize diabetes therapy data in innovative ways, providing notifications and alerts to users, their family, and caregivers. These software and application solutions cater to the same market as the insulin pumps, enhancing the overall user experience and management of diabetes.

Tandem Diabetes Care holds a strong position within the insulin delivery and diabetes technology industry. The company competes with other manufacturers of insulin delivery devices, including Beta Bionics, Insulet, Medtronic, mylife, and Sequel. Tandem's competitive advantages include its advanced Control-IQ+ technology, which is indicated for a broader age range and offers unique features such as AutoBolus and corrective bolusing. The company's commitment to innovation, as evidenced by its pipeline of next-generation products, including an extended-wear infusion site option for Mobi and a next-generation Mobi patch pump, further strengthens its position in the market. Tandem's extensive experience in CGM integration and its focus on providing customizable solutions also contribute to its competitive edge.

Tandem Diabetes Care's customer base primarily consists of people living with type 1 and type 2 diabetes who require intensive insulin therapy. The company serves customers in more than 25 countries, with a significant presence in the United States and Canada. Tandem's technology solutions are available through direct sales, customer support, and clinical teams in the United States and Canada, and through distributors in other markets. The company's increasing use of the pharmacy channel for reimbursement and coverage further expands its reach to customers. Tandem's commitment to providing flexibility and choice in intelligent insulin delivery systems ensures that it caters to a diverse range of customers with varying clinical needs and personal preferences.